Lonigutamab for Thyroid Eye Disease (TED)

Lonigutamab is a next-generation anti–insulin-like growth factor 1 receptor (anti-IGF-1R) —a humanized IgG1 monoclonal antibody designed for subcutaneous delivery. Unlike other anti-IGF-1R treatments, lonigutamab binds to a distinct epitope, triggering rapid receptor internalization and degradation of the receptor complex. Lonigutamab’s subcutaneous formulation allows for convenient, longer-term dosing, potentially enhancing clinical response depth and durability in patients with chronic disease.

As the first subcutaneous anti-IGF-1R therapy to demonstrate efficacy in TED comparable to IV-administered treatments, lonigutamab offers the potential for a convenient, best-in-class safety profile while retaining the clinically validated efficacy of an anti-IGF-1R.

The lonigutamab development program is currently being evaluated.